Search

everythinglearnresearchcommunity

for

Search:↓

A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

The user has been taking finasteride for nearly two months and has noticed an increased urge to urinate with slight discomfort. They are questioning if this side effect is temporary.

Personal experience with Procyanidin B2 shows it's ineffective for hair loss. Viviscal Pro supplement tablets, containing Procyanidin B2, didn't help after 8 months of use.

The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.

A 17-year-old is experiencing rapid hair loss from NW1.5 to NW3 in six months and feels dermatologists are unhelpful. They are using Minoxidil (Rogaine) and seeking advice on application.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

The user is experiencing rapid hair loss, progressing from Norwood 3 to 7, with thinning at the crown and receding hairline. Suggested treatments include finasteride, minoxidil, ketoconazole shampoo, and CBD with MCT oil.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The conversation discusses a study comparing pumpkin seed oil and 5% minoxidil topical foam for female pattern hair loss. The user is curious about the application regimen of pumpkin seed oil used in the study.

The user is seeking advice on hair transplant techniques and surgeons to reshape a natural widow's peak into a more rounded hairline, preferring long hair transplants with minimal scarring and maximum density. They are currently using finasteride and oral minoxidil, which have not been effective, and are considering various surgeons primarily in English-speaking countries and the EU, excluding Turkey.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The user has been using 1 mg finasteride for three months and recently started using 5% minoxidil once daily, resulting in new vellus hair growth. The user is hopeful that minoxidil will positively impact terminal hairs and is considering adding a derma stamp to the routine.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

A user's hair loss treatment progress over the last 6 months using finasteride, minoxidil and dermarolling; other users have commented to ask questions or share their own experiences.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.